Antibodies to *Candida albicans* in human cervicovaginal secretions

J. DOROTHY MILNE AND D. W. WARNOCK

From the Departments of Venereology and Microbiology, Bristol Royal Infirmary, Bristol

**SUMMARY** The incidence of IgA and IgG antibodies against *Candida albicans* was determined in cervicovaginal secretions from 95 non-pregnant women. IgG antibodies were detected in 21·2% of women with vaginal candidosis, in 23·5% of women harbouring yeasts in the vagina without clinical signs of infection, and in 26·6% of women not harbouring yeasts in the vagina. IgA antibodies were found in 6·1% of women with vaginal candidosis, in 5·9% of women harbouring yeasts in the vagina without clinical signs of infection, and in 8·9% of women not harbouring yeasts in the vagina. IgG antibodies against *C. albicans* were detected in the serum of all 95 women. It is suggested that a proportion of the antibodies found in the secretions was derived from the circulation.

**Introduction**

*Candida albicans* is a common cause of superficial cutaneous or mucosal infection in man. *C. albicans* is important as a pathogen because of its high incidence in normal persons in whom it forms part of the normal microbial flora of the mouth and intestinal tract. In women, vaginal candidosis is a common condition and this has led to interest in the use of serological tests as adjuncts to the usual clinical and microbiological methods of diagnosis of this infection (Stanley and Hurley, 1974; Warnock and Hilton, 1976; Jones and Warnock, 1977).

Antibodies to *C. albicans* have sometimes been detected in human cervical mucus (Parish et al., 1967) or cervicovaginal secretions (Govers and Girard, 1972; Waldman et al., 1972a). These antibodies have been found to belong to the IgA and IgG classes of immunoglobulin (Govers and Girard, 1972; Waldman et al., 1972a). It has been suggested that these antibodies might be the product of a local immunological response in the genital tract: application of *C. albicans* antigen to the cervical epithelium has been found to lead to the appearance of IgA and some IgG antibodies in the cervicovaginal secretions of normal women (Waldman et al., 1972b).

There is no information regarding the occurrence of IgA or IgG antibodies against *C. albicans* in the cervicovaginal secretions of women with proved vaginal candidosis. The incidence of these antibodies in the cervicovaginal secretions of women with vaginal candidosis and of other women is compared in this paper.

**Patients and methods**

**SUBJECTS**

Altogether 95 non-pregnant patients aged between 18 and 46 years were studied. These patients consisted of: 33 women with vaginal candidosis; these women had clinical signs of vaginitis or vulvovaginitis (vaginitis was recorded if any part of the vaginal mucosa was reddened or granular, vulvitis was recorded if any part of the vulva was reddened, swollen, fissured, or ulcerated) and a positive vaginal culture (*C. albicans* (31), *Candida tropicalis* (1), *Torulopsis glabrata* (1)); 17 women with no clinical signs of vulvitis or vaginitis but with a positive vaginal culture (*C. albicans* (16), *C. tropicalis* (1)); and 45 women with no clinical signs of vulvitis or vaginitis and a negative vaginal culture. None of these women had received local antifungal treatment during the preceding month.

The patients were further divided into two groups: those who were using oral contraceptives (in all cases this was a combined oestrogen/progestogen pill) and those who were not.
Collection of specimens

Five millilitres of blood were taken from each patient and the serum was separated and stored at 

\(-20^\circ\mathrm{C}\) until studied. A cervicovaginal washing was taken from each woman: 10 ml physiological saline was instilled into the cervical os and about 8 ml of mucus and saline were then aspirated. The washings were stored at \(-20^\circ\mathrm{C}\) until required, then centrifuged to remove debris, and concentrated 50 times using a Minicon B-15 concentrator (Amicon).

Antigen preparation

One strain of \(C.\) \(albicans\) group A (London School of Hygiene and Tropical Medicine 3153), maintained on glucose peptone medium, was used throughout this investigation. This strain was selected because it contains all the antigens of \(C.\) \(albicans\) group B and \(C.\) \(tropicalis\) (Hasenclever, 1965), and because it has antigens in common with \(T.\) \(glabrata\) (Hasenclever and Mitchell, 1960).

A cell suspension was prepared using 0-4\% formal saline to harvest the cells. The suspension was diluted to 12 000 cells per ml and stored at 4\(^\circ\mathrm{C}\) until used. One drop of this cell suspension was placed on each clean glass slide, dried at room temperature, and then flamed.

Indirect immunofluorescence test

Doubling dilutions of serum from 1:4 were made with phosphate buffered saline (pH 7.2). One drop of each serum dilution or concentrated cervicovaginal secretion to be tested was placed on each antigen preparation. The slides were incubated for 30 min at 37\(^\circ\mathrm{C}\) in a moist chamber before being rinsed in phosphate buffered saline for 10 min. Fluorescein-conjugated sheep anti-human IgA or IgG (Wellcome), diluted 1:5 with buffered saline, was placed on each slide and left for 30 min at 37\(^\circ\mathrm{C}\). The slides were rinsed in buffered saline and then mounted in buffered glycerol.

The highest dilution of serum giving a complete ring of bright green fluorescence around the cells was taken as the titre of the serum. In cases of doubt the test was repeated. Antibodies to \(C.\) \(albicans\) were considered to be present in samples of concentrated secretions if a definite ring of bright green fluorescence was visible around the cells.

Absorption of secretions

Sheep antiserum specific for human IgA or IgG (Wellcome) was added to samples of concentrated secretions containing IgA or IgG antibodies against \(C.\) \(albicans\) and incubated at 37\(^\circ\mathrm{C}\) for three hours and then at 4\(^\circ\mathrm{C}\) overnight. The absorbed samples were then centrifuged and the supernatant used in the immunofluorescence test.

Results

The incidence of IgA and IgG antibodies to \(C.\) \(albicans\) in the cervicovaginal secretions of the 95 patients is summarised in Table 1. The \(\chi^2\) test was used to calculate the significance of the results.

Antibodies in patients using oral contraception

There was no significant difference \(\chi^2 = 2.349, p<0.50\) in the incidence of IgG antibodies against \(C.\) \(albicans\) when women with vaginal candidosis were compared with women harbouring yeasts in the vagina without clinical signs of infection and with women not harbouring yeasts in the vagina. Similarly there was no significant difference \(\chi^2 = 1.003, p<0.70\) in the incidence of IgA antibodies when women with vaginal candidosis were compared with the other women.

Antibodies in patients not using oral contraception

There was no significant difference \(\chi^2 = 1.490, p<0.50\) in the incidence of IgG antibodies against \(C.\) \(albicans\) when women with vaginal candidosis were compared with women harbouring yeasts in the vagina without clinical signs of infection and with women not harbouring yeasts in the vagina. IgA antibodies were found in one woman with vaginal candidosis.

Table 1 Comparison of the incidence of IgG and IgA antibodies to \(C.\) \(albicans\) in cervicovaginal secretions of patients grouped according to diagnosis and the use of oral contraception

<table>
<thead>
<tr>
<th>No oral contraception</th>
<th>Oral contraception</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>No. of patients with</td>
</tr>
<tr>
<td></td>
<td>IgG antibodies</td>
</tr>
<tr>
<td>Vaginal candidosis</td>
<td>10</td>
</tr>
<tr>
<td>No signs of infection</td>
<td></td>
</tr>
<tr>
<td>yeast present in vagina</td>
<td>7</td>
</tr>
<tr>
<td>No signs of infection,</td>
<td></td>
</tr>
<tr>
<td>no yeast in vagina</td>
<td>12</td>
</tr>
</tbody>
</table>
EFFECT OF ORAL CONTRACEPTION ON THE INCIDENCE OF ANTIBODIES IN SECRETIONS

IgG antibodies against *C. albicans* were detected in 15 of 66 women using oral contraception compared with eight of 29 women who were not (*χ²=0.259, p<0.70). IgA antibodies were detected in six women using oral contraception and in one woman who was not (*χ²=0.940, p<0.50).

EFFECT OF TIME IN THE MENSTRUAL CYCLE ON THE INCIDENCE OF ANTIBODIES IN SECRETIONS

IgG antibodies against *C. albicans* were detected in eight of 29 women not using oral contraception. Antibodies were found in three of five women seen between days 1 and 10 of the menstrual cycle, in one of nine women seen between days 11 and 20, and in four of 15 women seen between days 21 and 30. The differences in incidence were not significant (*χ²=3.861, p<0.30).

IMMUNOFLUORESCENCE TESTS ON ABSORBED SECRETIONS

Nineteen samples of cervicovaginal secretions containing IgG antibodies against *C. albicans* were absorbed with sheep antiserum specific for human IgG. This resulted in the complete elimination of specific IgG fluorescence. There was no increase in specific IgA fluorescence after absorption of the IgG antibodies. Seven samples of secretions containing IgA antibodies to *C. albicans* were absorbed with antiserum specific for human IgA. This resulted in the complete elimination of specific IgA fluorescence. These tests established the specific nature of the reaction in the immunofluorescence test.

ANTIBODIES AGAINST *C. ALBICANS* IN SERUM

The relationship between the titre of circulating IgG antibodies against *C. albicans* and the presence of IgG antibodies in cervicovaginal secretions is presented in Table 2. IgG antibodies were detected in the secretions of 12 of the 73 women with a serum IgG titre of 1:4 or 1:8 compared with 11 of the 22 women with a serum IgG titre of 1:16 or 1:32 (*χ²=10.351, p<0.01).

Discussion

This investigation has demonstrated that IgG antibodies against *C. albicans* can be detected in the cervicovaginal secretions of some women with vaginal candidosis (21.2%). This incidence was similar to that observed in women harbouring yeasts in the vagina without clinical signs of infection (23.5%) and also to the incidence observed in women not harbouring yeasts in the vagina (26.6%). Altogether, IgG antibodies against *C. albicans* were detected in the cervicovaginal secretions of 22.0% of the women harbouring yeasts in the vagina. These antibodies could be the product of a local immunological response: local production of IgG antibodies against *C. albicans* has been demonstrated in normal women (Waldman et al., 1972b). However, the presence of IgG antibodies in a similar proportion of women not harbouring yeasts in the vagina (26.6%) suggests that these antibodies might not be the product of a local response.

*C. albicans* is part of the normal microbial flora of the mouth and intestinal tract and its presence on mucosal surfaces is often sufficient to stimulate the production of circulating antibodies in normal persons (Lehner, 1966; Warnock and Hilton, 1976; Jones and Warnock, 1977). The women in this investigation all had circulating IgG antibodies against *C. albicans*.

Is it possible that the IgG antibodies to *C. albicans* that were detected in the cervicovaginal secretions of our patients originated from the serum? The immunoglobulin content of the cervical mucus of individual women has been observed to change under endogenous hormonal influence (Schumacher, 1973) and it has been suggested that considerable amounts of serum IgG enter the cervicovaginal secretions of normal women (Schumacher, 1974). Most of the women in this investigation were taking combination oral contraceptives. Chipperfield and Evans (1975) detected higher concentrations of IgG and IgA in the cervical mucus of normal women using these contraceptives than in similar women not using oral contraceptives. Increased IgG:IgA ratios were detected in women using combination oral contraceptives, and this led to the suggestion that the hormonal effect is manifested through increased transudation of IgG from the circulation.

Our findings indicate that oral contraceptives do not affect the incidence of IgG antibodies to *C.
IgA antibodies against *C. albicans* were detected in the cervicovaginal secretions of a small proportion of the women in this investigation. IgA antibodies were detected in 6.1% of the women with vaginal candidiasis and this incidence was similar to that observed in women harbouring yeasts in the vagina without clinical signs of infection (5.9%) and also to the incidence observed in women not harbouring yeasts in the vagina (8.9%). Local production of IgA antibodies against *C. albicans* has been demonstrated (Waldman *et al.*, 1972b), but the presence of such antibodies in women not harbouring yeasts in the vagina suggests that these antibodies might not be the product of a local response.

IgA antibodies to *C. albicans* have been detected in the serum of normal persons (Lehner, 1970) and cervical mucus is thought to contain some IgA that has been derived from the circulation (Schumacher, 1974). Thus, it is reasonable to assume that a variable proportion of the IgA antibodies detected in the cervicovaginal secretions of our patients originated from the serum.

IgG and IgA antibodies to *C. albicans* can be detected in the serum of most normal persons but these antibodies do not appear to protect the host against *C. albicans* infection. Local production of IgA and IgG antibodies to *C. albicans* has been demonstrated in the genital tract of normal women (Waldman *et al.*, 1972b), but our observations suggest that antibodies derived from the circulation are also present in cervicovaginal secretions.

**References**


